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Diseases that affect the nervous system represent a great burden to society. Given the 
diverse etiology, designing neuroprotective strategies would provide a common 
therapeutic alternative for the prevention and treatment of these neurological conditions. 
In an attempt to understand the intrinsic mechanisms the brain possesses to maintain 
homeostasis and promote cell survival, our laboratory had previously discovered the 
AAA+ ATPase, Thorase. Using energy from ATP hydrolysis, Thorase regulates neuronal 
excitability through the internalization of AMPA receptors, and it maintains 
mitochondrial and peroxisomal integrity by extracting mislocalized proteins out of these 
organelles. Since the family of AAA+ ATPases is known for associating with diverse 
cellular functions, and the clinical manifestation of emerging pathogenic Thorase variants 
is miscellaneous, elucidating additional Thorase functions would help us better 
understand its neuroprotective effects and harness its therapeutic potential.  
 
In this study, we uncovered a novel role for Thorase in regulating mechanistic target of 
rapamycin complex 1 (mTORC1) signaling. We have shown that Thorase directly binds 
mTOR, thereby orchestrating the disassembly of the mTORC1. In the absence of 
Thorase, mTORC1 signaling and downstream processes were upregulated. Importantly, 
the mTORC1 hyperactivity observed in the absence of Thorase could be alleviated 
through the FDA-approved mTOR inhibitor rapamycin. Moreover, rapamycin 
substantially prolonged survival of mice lacking Thorase, which typically die of severe 
seizures shortly after birth. Collectively, these findings revealed a key role for Thorase as 
negative regulator of the mTORC1 signaling pathway that acts through the disassembly 
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of the mTORC1, thereby suggesting Thorase neuroprotective effects rely on maintaining 
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Chapter 1. Introduction 
According to estimates from the World Health Organization, neurological disorders 
including epilepsy and stroke constitute 6.3% of the global disease burden, a contribution 
steadily increasing when one compares past and future projections (years 2005 and 2015 
versus 2030). Among neurological disorders, over half of the burden in disability-
adjusted life years, a quantifiable measure for lost years of healthy life, is attributable to 
cerebrovascular disease, 12% to Alzheimer’s disease and other dementias and 8% to 
epilepsy. Neurological disorders are also a major cause of mortality and contribute to 
12% of total deaths globally, with cerebrovascular diseases accountable for 85% of these. 
 
Diverse molecular mechanisms underlie different neurological diseases that result in 
alteration of particular brain circuits or the death of specific neuronal populations. 
Accordingly, extensive research efforts are directed to the identification and 
understanding of disease-specific agents and mechanisms, with the aim of identifying 
druggable targets that may be approached in the clinic. For instance, researchers in the 
field of Parkinson’s disease aim to comprehend how alpha-synuclein aggregates and 
spreads throughout the brain, and investigators working on epilepsy seek to find the 
causes for excess brain excitability that underlie seizures.  
 
Finding specific disease-modifying therapeutic interventions is desirable. Alternatively, 
designing neuroprotective strategies would provide common therapeutic ground for the 
prevention and treatment of pathologically diverse degenerative processes. To enable 
this, it is crucial to dissect the intrinsic mechanisms the brain possesses to maintain 
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homeostasis and promote cell survival. Given the high metabolic demands of the brain, it 
will be especially interesting to lay out the principles that maintain neurons in a 
bioenergetically favorable state. 
 
AAA+ ATPase Thorase 
 
Discovery of the neuroprotective gene encoding for Thorase  
Preconditioning refers to the capacity of the nervous system to activate signaling 
pathways that promote cell survival upon sub-lethal insults, that prepare it for potential 
subsequent damaging episodes (Gidday, 2006). Using oxygen/glucose deprivation (OGD) 
and N-methyl-D-aspartate (NMDA) treatments to induce preconditioning in vitro, Dai 
and colleagues screened for genes that could confer neuroprotection in primary cortical 
neurons derived from rats (Dai et al, 2010). Twenty-eight genes were discovered and 
validated for their ability to prevent neuronal death against lethal OGD or NMDA 
treatment, among which was a gene of unknown function, AAA domain containing 1 
(ATAD1), a putative AAA+ ATPase. ATAD1 was re-named as Thorase, after the Norse 
god of thunder and lightning, Thor (Dai et al, 2010). 
 
Superfamily of AAA+ ATPases 
AAA+ ATPases (ATPases associated with diverse cellular activities) comprise of a large 
family of highly-conserved proteins found in all kingdoms of life (Hanson & Whiteheart, 
2005). AAA+ ATPases are referred to as “molecular motors” because they function 
analogously to an engine, transforming the chemical energy from ATP hydrolysis into 
mechanic force that induces an initial conformational change in the active site, which 
 3 
then propagates to distal subunits of the protein and then further to its interacting 
proteins. The conformational changes stemming from repeated cycles of ATP hydrolysis 
thus enable AAA+ ATPases to execute and participate in a myriad of functions, from 
protein unfolding, disaggregation and complex disassembly, to membrane trafficking, 
proteolysis or DNA replication. 
 
Among the extensively-characterized AAA+ ATPases, p97 exemplifies the versatility of 
the proteins within this family well (Stach & Freemont, 2017). p97 governs diverse 
functions in the cell, including membrane fusion, endoplasmic reticulum-associated 
degradation or NF-kappaB (nuclear factor kappa-light-chain enhancer of activated B 
cells) activation, among others. The functional ubiquity of 97 is enabled by its association 
with a multitude of adaptor proteins and cofactors that shuttle and assist it at different 
subcellular locations and with various substrates. At a specific site of action, p97 
harnesses the energy from ATP hydrolysis to extract and shuttle a given substrate from a 
cellular structure or complex for degradation. Unsurprisingly, mutations in p97 have been 
linked to clinically diverse neurodegenerative conditions, such as inclusion body 
myopathy, frontotemporal dementia, Amyotrophic Lateral Sclerosis (Johnson et al, 2010) 
or Parkinson’s disease (Tang & Xia, 2016). 
 
AAA+ ATPases are characterized by a core ATP-binding domain spanning 200-250 
amino acids. This domain contains the Walker A and B motifs, which are critical for 
binding and hydrolyzing ATP (Miller & Enemark, 2016). ATP hydrolysis depends on a 
conserved glutamate residue within the Walker B motif and mutation of this residue to 
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alanine therefore prevents ATP hydrolysis while still allowing for ATP binding. As ATP 
is required for substrate binding by most AAA+ proteins, Walker B mutants behave as 
“substrate traps” that bind but will not release substrates. Similarly, non-hydrolyzable 
ATP maintain AAA+ ATPases in the oligomeric substrate-bound state. In contrast, 
mutation of a conserved lysine residue within the Walker A motif disrupts ATP binding, 
therefore interfering with substrate binding (Hanson & Whiteheart, 2005).  
 
Members of the AAA+ ATPase family often assemble into oligomers with ATPase sites 
located at the interfaces of neighboring subunits, with adjacent subunits contributing 
residues to a bipartite active site (Sysoeva, 2017). While initial structural studies 
indicated that most AAA+ ATPases oligomerize into symmetrical hexameric rings, 
recent advances in structural techniques have evidenced that diversity also governs the 
arrangement of AAA+ ATPases. These alternative oligomeric structures include 
pentamers (clamp loader), heptamers (NtrC1), octamers (CED-4), helical filaments 
(DnaA) and non-symmetrical hexamers (NSF) (Sysoeva, 2017). 
 
The large scope of human diseases associated with AAA+ ATPases underscore their 
relevance in maintaining normal physiology. Aside from the maladies linked to p97 
mutations mentioned earlier, mutations in AAA+ ATPases involved in peroxisomal 
protein import underlie Zellweger’s type peroxisome-biogenesis disorders, a type of 
leukodystrophy with loss of myelin, the first AAA+ ATPase disease to be identified 
(Reuber et al, 1997). Torsin A, which resides in the lumen of the endoplasmic reticulum, 
is mutated in early-onset dystonia (Goodchild & Dauer, 2004). Aberrancies in Katanin, a 
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AAA+ protease that severs microtubules, causes hereditary spastic paraplegia (Evans et 
al, 2005).  
 
Structure and conservation of Thorase 
Since the discovery of Thorase as neuroprotective protein presenting homology to AAA+ 
ATPases, several studies have sought to characterize its structure, function and 
conservation across phyla.  
 
In humans, the gene for Thorase is located on the long arm of chromosome 10 
(10q23.31).  It encodes for a protein of 361 amino acids, with molecular weight of 
approximately 41 kDa. The protein contains a transmembrane domain at the N-terminal 
end and a highly conserved AAA+ domain toward the C-terminal end (Figure 1-1).  
 
Functions of Thorase unraveled heretofore  
Thorase orchestrates the removal of AMPAR from postsynaptic membranes 
In a landmark Thorase study published in 2011, Zhang and colleagues explored the 
distribution of Thorase in different tissues. They detected highest expression in brain and 
testes. Within the brain, Thorase expression levels were found to be heterogenous, with 
pyramidal cells in the CA1 region of the hippocampus expressing it in relatively high 
levels (Zhang et al, 2011). Subcellularly, Thorase was enriched at synapses and co-
localized with postsynaptic markers like PSD95.  
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In postsynaptic membranes, presence of the ionotropic glutamate α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) partially determines the strength of 
a synapse, and neuronal excitability can be controlled by regulating the insertion or 
removal of these receptors (Moretto & Passafaro, 2018). Through a series of biochemical, 
imaging and electrophysiological experiments, the authors demonstrated that Thorase 
facilitates the endocytosis of GluA2 subunit-containing AMPARs from synapses. ATP 
binding and hydrolysis were necessary for Thorase to disassemble GluA2 subunits from 
GRIP1 at postsynaptic membranes (Figure 1-2A).  
 
The whole-body homozygote Thorase knockout mice created for this study were viable 
but approximately 80% died of a seizure-like syndrome within 3 weeks after birth, and 
were significantly smaller in size than their wild type littermates since birth. 
Heterozygous knockout mice showed no obvious developmental or behavioral 
abnormalities and were viable. Mice lacking Thorase had increased postsynaptic 
AMPARs without an alteration in AMPAR subunit composition, with consequent 
increases in AMPA but not NMDA postsynaptic currents. Primary cortical neuron 
cultures from these mice presented with higher baseline levels of surface AMPAR that 
could further be increased with tetradotoxin, while their bicuculline-induced 
internalization was impaired, indicating an impediment of AMPAR endocytosis, but not 
insertion. These defects could be reduced by heterologous expression of Thorase. 
Behaviorally, this excess AMPAR maintenance at the synapses resulted in enhanced 
long-term potentiation and impaired long-term depression of synapses, with profound 
effects on learning and memory. 
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A study published shortly after suggested a possible regulation of the interaction between 
Thorase and other AMPAR-trafficking complexes (ATCs) by gangliosides (Prendergast 
et al, 2014). Specifically, this study found that while GluA2 binds selectively to 
ganglioside GM1, Thorase and other ATC proteins bind ganglioside GT1b, through the 
adapter protein Nicalin, potentially keeping these components physically separated as a 
means to control AMPAR endocytosis. In vivo, mice carrying mutations in ganglioside 
biosynthesis enzymes found in human congenital disorders with early onset seizures have 
altered ganglioside membrane compositions, and AMPAR and ATC binding dynamics.   
 
Thorase participates in the quality and control of mitochondria and peroxisomes 
In a radically different set of discoveries, Thorase emerged as an important component in 
the maintenance of healthy peroxisomes and mitochondria. In a pair of back-to-back 
publications, Thorase and its yeast homolog Msp1 were found to be required to prevent 
the aberrant accumulation of a subset of proteins, the tail-anchored (TA) proteins, in the 
mitochondria, thereby maintaining mitochondrial health and integrity (Chen et al, 2014; 
Okreglak et al, 2014) (Figure 1-2B). These composite of research studies show the high 
degree of functional conservation of Thorase in yeast, flies and mammals (Figure 1-1).  
 
Tail-anchored proteins are post-translationally chaperoned to either mitochondria or the 
endoplasmic reticulum, from where they are subsequently shuttled into other membrane 
compartments such as the peroxisome, by a dedicated system called the Guided Entry of 
Tail-anchored proteins (GET).  
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Loss of yeast Msp1, which was otherwise found to be integrally embedded in the outer 
mitochondrial membrane, led to the accumulation of the peroxisomal TA protein Pex15 
in mitochondria, which was exacerbated upon deletion of GET proteins. Steady state 
levels of Pex15 were higher and its degradation rate slower in the absence of Msp1, 
indicating that Msp1 promotes the degradation of mislocalized proteins concomitant to 
their extraction from their non-cognate organelles. In support of this, Msp1 and Pex15 
were proven to physically interact. These observations were validated with the human 
homologs, ATAD1 and PEX26. 
 
Besides the accumulation of mislocalized TA proteins, the brains of Thorase knockout 
mice have lower levels of several mitochondrial proteins and reduced respiratory 
mitochondrial capacity, alongside with aberrant mitochondrial morphology and 
fragmentation. Loss of Msp1 also induced a failure to grow on certain carbon sources, a 
phenotype that could be partially rescued by ectopic expression of the Drosophila 
melanogaster homolog Dmel\nmd. 
 
Two subsequent studies aimed to gain further insight into how Msp1 may extract 
mislocalized TA proteins from mitochondria. Wohlever and colleagues showed, using in 
vitro reconstituted proteoliposomes, that Msp1 alone could extract TA proteins from the 
membrane in an ATP-dependent manner, without the assistance of any other factors. 
Crystal structure of the cytosolic end of Msp1 revealed a ring-shaped hexamer with a 
central pore facing the membrane. Mutations of pore-forming residues or mutations that 
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impeded the ring formation disrupted the ability of Msp1 to extract proteins from the 
liposomes (Wohlever et al, 2017).  In the more recent publication authored by Li and 
colleagues, the mechanism by which Msp1 recognizes mislocalized TA proteins was 
proposed. Presumably, mislocalized TA proteins expose hydrophobic surfaces, which 
Msp1 can detect through its N-domain. This recognition triggers the rearrangement of 
Msp1 monomers into active hexamers that can hydrolyze ATP to dislocate the substrate 
(Li et al, 2019). Although the membrane extraction function of Msp1 seems to be 
conserved in mammals, it will be interesting to see whether these findings are applicable 
to Thorase/ATAD1. 
 
A study conducted by Liu and colleagues showed that Thorase is targeted to peroxisomes 
and suggested that it may perform a quality and control function there similar to the one 
described in mitochondria (Liu et al, 2016). 
 
Emerging importance of Thorase in human disease 
In 2017, the first pathogenic variant of human Thorase was reported in a consanguineous 
Kuwaiti family with multiple newborns suffering from seizures, encephalopathy, 
hypertonia and respiratory failure that led to early death (Ahrens-Nicklas et al, 2017).  
 
Pedigree analysis suggested an autosomal recessive inheritance pattern, and exome 
sequencing followed by single nucleotide polymorphism analysis linked a novel 
homozygous variant of Thorase to the affected probands, which was carried by the 
unaffected parents. This homozygous transversion (826 G>T) predicted a substitution of 
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a glutamic acid residue to a premature stop codon (E276X). In lymphoblasts from 
patients, Thorase mRNA levels were greatly decreased and Thorase protein was 
undetectable by Western blotting, reportedly because the early polypeptide termination 
would trigger the degradation of mRNA through nonsense-mediated decay.  
 
Consistent with a potential pathogenic loss-of-function conferred by this novel human 
variant, there was overlap between the clinical manifestation of the affected neonates and 
the phenotype of homozygous Thorase knockout mice, including seizures and early death 
(Zhang et al, 2011). Based on this resemblance, and the known role of Thorase in 
AMPAR recycling, it was postulated that the FDA (Food and Drug Administration)-
approved AMPAR antagonist, Perampanel, may provide therapeutical benefit in Thorase-
deficient mice and newborns carrying loss-of-function Thorase variants. 
 
Treatment of Thorase knockout mice with Perampanel decreased the excess spontaneous 
locomotor activities and extended their survival, while off-label compassionate treatment 
of affected individuals with Perampanel resulted in an improvement in the tone in 
patients and stopped seizures. One of the probands had severe neurological symptoms at 
the time he was treated with Perampanel, at 16 months of age. While his hydrocephalus 
(accumulation of cerebrospinal fluid) continued worsening, Perampanel improved his 
tone and reflexes including his pupillary response to light, while his brain activity 
monitored via electroencephalogram (EEG) normalized. A cousin of this patient was 
treated early at 2.5 months of age, before her neurological functions had severely 
declined. Perampanel improved her hypertonia, normalized her EEG activity and she 
 11 
maintained some basic responses such as the brain stem reflexes, the ability to vocalize 
pain and her spontaneous limb movements. 
 
Prior to this seminal study on a pathogenic mutation in Thorase/ATAD1, the gene was not 
known to be associated with human disease. Within 2 years from this case report, 
additional families have been identified that carry pathogenic variants in Thorase. 
Collectively, Thorase mutations are currently categorized by the Online Mendelian 
Inheritance in Man database under a hyperekplexic phenotype, or congenital stiff-baby 
syndrome (OMIM entry # 618011). The severity of the clinical cases underscores the 
pivotal role of Thorase in maintaining normal physiology, especially in the brain, while 
the broad clinical manifestations grant further research to elucidate whether different and 
yet unknown functions of Thorase may be responsible for the pathological discrepancies. 
 
Mechanistic Target of Rapamycin kinase 
 
mTOR (mechanistic Target Of Rapamycin) is a highly conserved kinase that links the 
growth, survival, division, migration and differentiation of cells to the availability of 
nutrient and growth factors in the environment that they are in. mTOR does so by acting 
as master switch that balances the activation of energy-producing and -consuming 
metabolic activities. mTOR is a central signaling hub in cells and, as such, a wide range 
of human diseases have been attributed to aberrant function of its pathway. 
 
Discovery of mTOR 
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In the 1960s, a group of expeditioners collected soil samples in the Chilean Easter Island 
(also known as Rapa Nui), in search for novel antimicrobial compounds. Among these 
they found the eponymous macrolide, rapamycin, which they isolated from Streptomyces 
hygroscopicus and possessed potent antifungal, antitumoral and immunosuppressive 
effects (Vézina et al, 1975; Martel et al, 1977; Eng et al, 1984). 
 
In parallel efforts to identify the cellular target of rapamycin, genetic screens in yeast and 
biochemical approaches in mammals led to the discovery of the Target of Rapamycin 
(TOR), a highly conserved serine/threonine kinase with homology to the PI3K-related 
protein kinases (PIKKs) (Koltin et al, 1991; Heitman et al, 1991; Sabatini et al, 1994; 
Brown et al, 1994; Sabers et al, 1995). Rapamycin binds and inhibits mTOR allosterically 
in complex with FKBP12. 
 
In the 25 years since its discovery, tremendous progress has been made to elucidate the 
molecular and biochemical mechanisms centered around mTOR, including cofactors, 
downstream kinase targets, the biochemical processes regulated by these phosphorylation 
events, and the cues and molecular stakeholders that activate and inhibit the pathway 
(Sabatini, 2017; Valvezan & Manning, 2019). 
 
mTOR signaling pathway 
mTOR is the catalytic component of two functionally distinct macromolecular 
complexes, the mTOR complex 1 (mTORC1) and the mTORC2. Raptor (Regulatory 
associated protein of mTOR) and Rictor (Rapamycin-insensitive companion of mTOR) 
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are defining protein components of mTORC1 and mTORC2, respectively, and are 
thought to enable mTOR kinase activity by acting as scaffolds for recruiting mTOR 
substrates (Hara et al, 2002; Kim et al, 2002, Sarbassov et al, 2004).  
 
Comparably much less is known about the mTORC2, which through the activation of the 
PI3K/AKT signaling pathway controls the arrangement of the actin cytoskeleton and 
plays a role in the survival, proliferation and migration of cells.  
 
In contrast, mTORC1 has been studied in depth. mTORC1 activity stimulates metabolic 
processes that synthesize macromolecules (anabolic), while it inhibits those that lead to 
their breakdown (catabolic). For instance, mTORC1 induces protein synthesis via 
promoting the translation of specific mRNAs that encode for proteins of the translation 
machinery (5’ terminal oligopyrimidine tract mRNAs), and by promoting ribosome 
biogenesis (Ma & Blenis, 2009). Among the translational kinase targets of mTORC1 are 
ribosomal S6 kinases (S6K) and the eukaryotic translation initiation factor 4E-binding 
proteins (4EBP). 4E-BP binding to eIF4E blocks the recruitment of the small ribosomal 
subunit to the mRNA 5’ cap. mTOR phosphorylation of 4E-BP releases it from eIF4E, 
thereby allowing for translation initiation. S6K owes its name to its substrate ribosomal 
protein S6, although how this phosphorylation promotes translation remains a mystery. 
S6K also phosphorylates another eukaryotic initiation factor, eIF4B, which in turn 
stimulates the helicase activity of its partner eIF4A, leading to the translation of mRNAs 
with complex untranslated regions.  
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Ribosomes are large molecular machines where the catalytic component relies in the 
activity of RNAs. Therefore, an increase protein synthesis has to be accompanied with 
transcription of ribosomal RNAs and synthesis of nucleotide building blocks, both of 
which are also the result of mTOR activation (Iadevaia et al., 2014; Ben-Sahra et al, 
2014; Robitaille et al, 2013). In parallel, mTORC1 also stimulates the synthesis of lipids 
through the activation of the Sterol Regulatory Element-Binding Protein (SREBP) family 
of transcription factors (Porstmann et al, 2008). 
 
As mTORC1 becomes active, autophagy and lysosomal function, which are integral parts 
of the degradation machinery in the cell, arrests. mTORC1 accomplishes this by 
phosphorylating the autophagy-initiating kinase UNC-51-like kinase 1 (ULK1) and the 
transcription factor EB (TFEB), a master regulator of lysosome biogenesis (Egan et al, 
2011; Peña-Llopis, 2011). 
 
Regulation of mTORC1 activity 
Recent studies have provided great mechanistic insight into where and how mTORC1 is 
activated (Valvezan & Manning, 2019). A small G protein, Rheb, can directly bind and 
activate mTORC1, potentially through conformational changes that activate the kinase 
activity of mTOR (Yang et al, 2017). Only when bound to GTP, but not GDP, Rheb can 
exert its activating effects on mTORC1. Therefore, the stimuli that impinge upon the 
activation state of mTORC1 converge in the regulation of the GTP/GDP-bound state of 
Rheb, through the tuberous sclerosis (TSC) complex, which comprise proteins TSC1, 
TSC2 and TBC1D7. TSC2 has a GTPase-activating protein (GAP) activity towards 
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Rheb, whereby it inactivates it (Figure 1-3A). Several kinases stimulated by either growth 
factors or different kinds of stress cues phosphorylate and influence the activity of the 
TSC complex, thereby connecting extracellular and intracellular signaling (Dibble & 
Manning, 2013).  
 
A subpopulation of Rheb proteins can be found at the lysosome, where mTORC1 needs 
to be shuttled for activation. A pair of antagonizing small G protein heterodimers, the 
RagA/B and RagC/Ds proteins, are responsible for the regulated recruitment of mTORC1 
to the lysosome through their interaction with Raptor (Sancak et al, 2008). Rag GTPases 
localize to the lysosome through yet another protein complex, the Ragulator (also known 
as LAMTOR) and a lysosomal amino acid transporter, SLC38A9 (Sancak et al, 2010). 
Similar to Rheb, the activity or Rag proteins is also regulated by their GTP/GDP-bound 
status, with RagA/Bs specifically active in the GTP-loaded state and Rag C/Ds active in 
the GDP-loaded state (Figure 1-3A). Therefore, modulating the nucleotide state of the 
Rag proteins impacts mTORC1 activation at the lysosome. The Rag protein nucleotide-
loading regulation network is sensitive to intracellular amino acid levels, the building 
blocks for the synthesis of proteins, which is the most energy- and nutrient-demanding 
biosynthetic process. GAP activity toward Rags 1 (GATOR1) anchors to the lysosome 
through a protein complex called KICSTOR, and exerts its GAP activity towards RagA/B 
in the absence of amino acids, thereby preventing mTORC1 recruitment to the lysosome 
(Bar-Peled et al, 2013; Panchaud et al, 2013; Wolfson et al, 2017). GATOR1 can be 
inhibited by SAMTOR, which senses the levels of S-adenosylmethionine, a proxy for 
methionine levels in the cell (Gu et al, 2016). Another protein called GATOR2 can also 
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inhibit GATOR1, only in the presence of arginine and leucine, in which case GATOR2 is 
not sequestered by their respective protein sensors, CASTOR1 and Sestrin2 
(Chantranupong et al, 2016; Wolfson et al, 2016). 
 
In summary, both amino acid and growth factors are required for mTOR activation, a co-
requisite which is integrated through the so-called AND-gate signaling, where the 
presence of amino acids allows GTP-bound RagA/Bs to recruit mTORC1 proximally to 
Rheb, which will in turn be GTP-loaded if growth factors stimulate the release of TSC 
complexes away from the lysosome (Menon et al, 2014) (Figure 1-3B). 
 
While many details about how mTOR is activated at the lysosome are known, it is less 
clear where and how the complex gets inactivated. Given the different layers of 
regulation participating in the regulation of mTORC1 assembly and activation, it is 
reasonable to expect that the disassembly of the complex would also involve dedicated 
proteins that respond to nutrients, growth factors, energy levels or stress. 
 
mTOR in disease 
Given the central role of mTOR in the growth, metabolism and survival of cells, it is not 
surprising that dysregulation of the signaling pathway has been suggested to underlie 
radically disparate pathogenic processes, including cancer, diabetes to autism or 
Parkinson’s disease (Saxton & Sabatini, 2017).  
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As one of the most energy-demanding organs in the body, the brain is particularly 
susceptible to metabolic dysregulation (Lipton & Sahin, 2014). In neurodegenerative 
processes, aberrant mTOR signaling may contribute in different ways. On one hand, 
excess mTOR activation could overshoot neurons with the demands of protein synthesis, 
which could saturate the chaperones that ensure proper protein folding.  On the other 
hand, blockade of autophagy by active mTOR could impair the clearance of damaged 
organelles and protein aggregates. During development, incorrect migration or 
differentiation of neurons and failed synapse formation may subvert neural circuit 
formation. 
 
A considerable amount of mutations in mTOR pathway components have been found in 
the particular case of epilepsies associated with malformations of cortical development, 
which have collectively been coined as “mTORophathies” (Crino, 2015). Mutations in 
several genes like TSC2, GATOR1 or mTOR itself in these epilepsies seem to all have in 
common that they lead to a hyperactivation of mTORC1, which may trigger onset of 
seizures due to abnormal arrangement of the cortical laminae, cell size and lineage 
commitment or impinging upon neuronal excitability itself (Crino, 2016; Baulac, 2016). 
Accordingly, the use of mTOR inhibitors has been explored in the clinic, with some 
promising results (Citraro, 2016).  
 18 





Figure 1-1. Protein sequence alignment of Thorase homologues. Protein sequence 
alignment of Thorase (H. sapiens) and its homologues, ATAD1 in mouse (M. musculus), 
Dmel\nmd in the fruit fly (D. melanogaster) and Msp1 in budding yeast (S. cerevisiae) 
aligned with ClustalW and rendered with Boxshade. Identical residues are highlighted in 
black and similar ones in gray. Residues within canonical AAA+ ATPase domains are 
shown in an orange box. The span of the ATPase domain is indicated with a brown line, 





Figure 1-2. Schematic depicting known Thorase functions. 
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Figure 1-2. Schematic depicting known Thorase functions. A, in postsynaptic 
membranes, in an ATP-dependent manner, Thorase stimulates the endocytosis of GluA2 
subunit-containing AMPA receptors by disrupting its interaction with GRIP1, thereby 
regulating neuronal excitability. B, in mitochondria, in an ATP-dependent manner, 
Thorase recognizes tail-anchored proteins that have been erroneously targeted to the 
outer mitochondrial membrane, and ensures organellar integrity by extracting them and 
promoting their degradation. This illustration was created using BioRender and adapted 
from Pignatelli et al (2017) and Hegde (2014). 
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Figure 1-3.  Schematic summarizing mTORC1 regulation. A, different small G 
proteins regulate the activation of mTORC1.  RagA/B and RagC/Ds, and their activation 
depends on their nucleotide-binding status, with RagA/Bs active when bound to GTP, 
and RagC/Ds active when bound to GDP. GATOR1 stimulates the inactivation of Rag 
proteins, while Ragulator induces their activation. GTP-bound Rheb can directly activate 
mTORC1 activity, and the TSC complex prevents this with its GTPase Activating Protein 
(GAP) activity towards Rheb. B, Both amino acids and growth factors are required for 
full mTOR activation (AND-gate signaling). In the absence of amino acids and growth 
factors, GATOR1 and TSC complexes inhibit RagA/Bs and Rheb, respectively, by 
stimulating their GTPase activity. In the presence of growth factors alone, the TSC 
complex is phosphorylated and thus released from the lysosome. In the presence of amino 
acids alone, leucine-sensing Sestrin and arginine-sensing CASTOR impede the inhibitory 
effects of GATOR2 over GATOR1, and SAM-loaded SAMTOR no longer stimulates 
GATOR1 GAP activity, and therefore Rag proteins can recruit the mTORC1 to the 
surface of the lysosome. However, the concomitant presence of TSC complex at the 
lysosome inhibits mTORC1 activation through its inhibitory effects on Rheb. In the 
presence of both amino acids and growth factors, mTORC1 can be recruited to the 
lysosome and be directly activated by GTP-loaded Rheb. This illustration was created 
using BioRender and adapted from Valvezan & Manning (2019).
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Chapter 2. Characterization of the effects on 
mitochondrial function of a novel homozygous ATAD1 
mutation linked to a lethal encephalopathy in neonates 
Introduction 
ATAD1/Thorase was recently discovered as neuroprotective protein that belongs to the 
superfamily of AAA+ ATPases, involved in the unfolding of proteins and disassembly of 
protein complexes and aggregates, amongst other functions. In postsynaptic membranes, 
Thorase promotes the internalization of AMPA receptors by disrupting the interaction of 
AMPA receptor subunit, GluA2 and the AMPA receptor-binding protein, GRIP1 (Zhang 
et al, 2011). In mitochondria and peroxisomes, Thorase ensures the extraction of tail-
anchored protein that are mislocalized, particularly upon cellular stress.  
 
Recently, the first pathogenic human variant in Thorase linked to a congenital disease 
presenting with severe hypertonia, seizures, and death in a consanguineous family was 
reported (Ahrens-Nicklas et al, 2017). Supportive of its emerging importance in 
neurological disease, here we report a second pathogenic Thorase variant linked to a 
lethal encephalopathy affecting 3 newborn siblings in a consanguineous family. Exome-
sequencing and subsequent variant analysis under an assumed recessive pattern of 
inheritance revealed a 2 base-pair deletion (c.1070_1071delAT), resulting in a frameshift 




In order to establish a relationship between genotype and phenotype for this new variant, 
we performed a series of biochemical assays to determine whether any of the known 
Thorase functions was affected and may therefore explain the severe clinical 
manifestations in the 3 siblings that ultimately led to their early death.  
 
Results 
Mutant Thorase is expressed in patient-derived fibroblasts 
ATAD1 mRNA analysis from patient fibroblasts had suggested that, as a consequence of 
the frameshift, additional amino acid residues would be incorporated at the C-terminal 
end of the protein. To assess whether this altered C-terminal end of the protein would 
affect global protein stability, we examined the amount of ATAD1 protein in patient cells 
via immunoblotting. We observed no significant changes in the total levels of ATAD1 
protein, suggesting that the altered protein product escaped cellular degradation (Figure 
2-1).  
 
The ATAD1 mutation p.(His357Argfs*15) leads to reduced amounts of some 
mitochondrial proteins in patient-derived fibroblasts 
Previously, ATAD1 deletion in human cell lines was shown to cause an accumulation of 
peroxisomal biogenesis factor 26 (PEX26) and Golgi SNARE 28 kDa (GOS28) (Chen et 
al, 2014). In patient cells expressing C-terminal mutant Thorase, we found PEX26 
protein levels were slightly lower compared to cells derived from healthy individuals. In 
addition, other mitochondrial proteins, including cytochrome c oxidase subunit 4 
(COX4), hexokinase 1 (HXK1), and voltage-dependent anion channel 1 (VDAC1) were 
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also reduced (Figure 2-2). Thus, the frameshift mutation in ATAD1 seems to affect the 
stability or expression of peroxisomal and mitochondrial proteins.  
 
Discussion 
Combined with the results from other experiments, these data contributed to our recent 
report that pathogenic p.(His357Argfs*15) confers a gain-of-function to ATAD1, 
reportedly by locking the protein in an active oligomeric state without interfering with its 
ATP binding or hydrolyzing activity (Piard et al, 2018). Although the levels of several 
proteins were reduced compared to controls, mitochondrial morphology and respiratory 
capacity seemed unaltered. In contrast, cross-linking and imaging experiments with 
primary cortical cultures expressing the mutant form of Thorase ectopically showed 
reduced surface levels of AMPAR subunit GluA2, suggesting that mutant Thorase may 
induce excessive internalization of AMPA receptors. 
 
Our previous report on a pathogenic mutation of Thorase (p.Glu276*) phenotypically 
resembled the loss-of-function in mouse models of Thorase deficiency. Surprisingly, 
there was extensive overlap clinically between the probands of both consanguineous 
families, including muscle stiffness since birth. This suggests that perhaps this C-
terminally extended form of Thorase may act as dominant negative form for some but not 
all functions of the AAA+ ATPase. 
 
Given the striking clinical parallelisms between a girl born to consanguineous parents in 
1992 with congenital stiffness and the patients described in the reports by Ahrens-Nicklas 
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and Piard, Wolf and colleagues performed targeted Sanger sequencing of ATAD1 in 
muscle DNA isolated from the patient. This revealed a homozygous mutation at the last 
nucleotide of the second exon (c.162G > C), which was predicted to replace the highly 
conserved amino acid glutamine at position 54 to histidine (p.Gln54His) or to disrupt the 
splicing due to removal of the splice donor site of intron 2 (Wolf et al, 2018). Although 
this mutation would likely result in a loss of protein function, genotype-phenotype studies 
to validate this hypothesis would be necessary.  
 
Given these three reports, ATAD1 is now established as a hyperekplexia (congenital 
stiffness) disease-causing gene. 
 
Material and Methods 
Maintenance of patient- and control-derived fibroblasts 
Fibroblasts were maintained in Dulbecco’s modified Eagle medium (DMEM, Corning 
Cellgro) plus 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) Penicillin-Streptomycin 
(Corning Cellgro), at 37oC with a 5% CO2 atmosphere in a humidified incubator.  
 
Measurement of peroxisomal and mitochondrial protein expression 
Thorase expression and comparative immunoblot analyses were performed using cell 
lysates from patient and control fibroblasts. Protein concentrations were determined by 
BCA protein assay (PierceTM, Thermo Scientific) and 20 mg were resolved on SDS-
PAGE gels. Immunoblot membranes were stained with Ponceau solution to ensure equal 
loading of protein samples. Immunoblot analyses were performed using antibodies to 
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COX4, Hexokinase 1 (HXK1), PEX26, VDAC1 and actin (Sigma) as control for loading. 
Band intensities were quantified using ImageJ (NIH) and normalized to actin. The values 
obtained from ImageJ were further analyzed to determine significant differences using 
GraphPad Prism software (GraphPad). 
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affects the oligomeric state of
Thorase but causes no defects in its
ATPase activity
The predicted 3D model of Thorase suggests that the
ATAD1 mutation p.(His357Argfs*15) results in changes
in the secondary structure at the C-terminus of Thorase
(Fig. 3D). The wild-type C-terminus (Ala349-Asp361) is
predicted to form a helix, while in the Thorase
mutantHis357Argfs*15 the helix is shortened and sandwiched
by two loops to form a loop-helix-loop (LHL) structure
(Fig. 3D). To further examine the activity of the Thorase
mutantHis357Argfs*15, a recombinant expression vector
encoding for it was generated. Purified wild-type Thorase
elutes as 70 kDa (dimer) on a size-exclusion column, while
the mutantHis357Argfs*15 elutes at a higher molecular weight
4400kDa (Fig. 3E). Thus, the p.(His357Argfs*15) muta-
tion seems to lock the Thorase mutant in an oligomeric
state. Both wild-type and mutant migrated at !36 kDa in
SDS-PAGE as indicated by Coomassie staining and immu-
noblot analysis, however, the mutant migrated higher than
the wild-type due to the elongated C-terminus (Fig. 3F).
ATP binding assessment using UV light-induced cross-link-
ing (Harvey et al., 2008) of radiolabelled [a-P32]ATP
bound to purified recombinant proteins suggested that the
Thorase mutant binds ATP similar to wild-type
(Supplementary Fig. 2). Similarly, ATP hydrolysis was not
significantly affected in the mutant (Supplementary Fig. 2).
These results indicate that the p.(His357Argfs*15) muta-
tion does not affect ATPase activity of Thorase but strongly
impacts its oligomeric state, most likely as a result of the
LHL formation at the C-terminus.
The Thorase mutantHis357Argfs*15
shows defects in the disassembly of
AMPAR-GRIP1 and Thorase
oligomer complexes
Since Thorase regulates AMPAR trafficking (Zhang et al.,
2011; Prendergast et al., 2014), we examined Thorase
mutantHis357Argfs*15 interactions with GluA2-GRIP1 com-
plex and particularly its disassembly. Purified GST-
Thorase wild-type and mutant were immobilized on beads
and mixed with Thorase knockout (Atad1"/") whole brain
lysates in the presence of ADP, ATP or ATP!S (Fig. 4A–D).
Both wild-type and mutant bound efficiently to the GluA2-
GRIP1 complex in the presence of non-hydrolysable
ATP!S, which maintains Thorase in the oligomeric sub-
strate-bound state (Fig. 4A–C). However, in the presence
of ATP, which can be hydrolysed and is required for the
proper disassembly of protein complexes by Thorase, wild-
type Thorase disassembled the complex, whereas the disas-
sembly was significantly impaired by the Thorase
mutantHis357Argfs*15 (Fig. 4D). These data suggest that the
p.(His357Argfs*15) mutation affects Thorase-mediated
AMPAR trafficking, likely by impairing its transition
from oligomeric to monomeric state. The formation of oli-
gomeric complexes by Thorase and other AAA+ ATPases
is critical for their proper assembly and disassembly of pro-
tein complexes (Fujiki et al., 2008). Therefore, we at-
tempted to determine whether the defect in AMPAR
complex disassembly by the mutantHis357Argfs*15 results
from improper Thorase oligomer disassembly. Oligomeric
formation and disassembly were evaluated by ATP binding
and glutaraldehyde cross-linking of protein complexes
(Babst et al., 1998). Purified Thorase samples were mixed
with ATP (at 4#C to prevent its hydrolysis or at 37#C to
allow for its hydrolysis) or non-hydrolysable ATP!S
(Supplementary Fig. 2). In the presence of either ATP at
4#C (ATP-4) or ATP!S Thorase formed large oligomeric
complexes of molecular weights greater than 250 kDa
(Supplementary Fig. 2). While 71 $ 4.7% of Thorase
wild-type formed oligomers, 89 $ 6.3% of the mutants
were found in the oligomeric state (ATP-4 in
Supplementary Fig. 2). Upon ATP hydrolysis (ATP-37),
75.5 $ 4.4% of Thorase wild-type and 57.6 $ 7.6% of
mutant disassembled oligomeric complexes (Supplementary
Fig. 2). These results indicate and further confirm that the
p.(His357Argfs*15) mutation impairs normal disassembly
of Thorase oligomers. Although we observed a defect of
14–18% in oligomeric disassembly in the Thorase
mutantHis357Argfs*15 compared to wild-type, this may be
significant enough to cause severe consequences in terms
of clinical phenotype.
Figure 2 Mutant Thorase is expressed in patient-derived
fibroblasts. (A) Immunoblot of lysates obtained from patient and
control fibroblasts. Expression of Thorase was monitored by using
anti-Thorase antibody, and anti-actin antibody was used to control
for equal loading. As the anti-Thorase antibody was generated
against the C-terminus and this region contains a new amino acid
composition in the mutant, detection of Thorase in patient cells was
difficult (compare the clear band in control and the diffuse band in
patient cells). (B) Optical densitometry quantification of A. Values
represent the mean $ SEM (n = 3, n.s. P4 0.05, Tukey’s multiple
comparison tests).
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Figure 2-1. Mutant Thorase is expressed in patient-derived fibroblasts.  
A, Immunoblot of lysates obtained from patient and control fibroblasts. Expression of 
Thorase was monitored using anti-Thorase antibody, and anti-actin antibody was used to 
control for equal loading. As the anti-Thorase antibody was generated against the C-
terminus and this region contains a new amino acid composition in the mutant, detection 
of Thorase in patient cells was difficult (compare the clear band in control and the diffuse 
band in patient cells). B, Optical densitometry quantification of A. Values represent the 
mean +/- SEM (n = 3, n.s. P > 0.05, Tukey’s multiple comparison tests).  
 3 1  
Fi g u r e 2 -2. T h e A T A D 1 m ut ati o n p.( His 3 5 7 A r gfs * 1 5) l e a ds t o r e d u c e d a m o u nt s of 
s o m e mit o c h o n d ri al p r ot ei ns i n p ati e nt -d e ri v e d fi b r o bl asts . 
 
At a d 1 / n e u r o n s e x p r e s si n g t h e
T h o r a s e  m u t a n t Hi s 3 5 7 A r gf s * 1 5 di s pl a y
r e d u c e d  Gl u A 2 s u rf a c e e x p r e s si o n
Si n c e  T h or as e r e g ul at es s urf a c e e x pr essi o n of  A M P A Rs t h e
eff e cts of t h e p.( His 3 5 7 Ar gfs * 1 5)  m ut ati o n o n  A M P A Rs
tr af Þ c ki n g  w as e v al u at e d.  A n a nti b o d y-f e e di n g ass a y f or
e n d o c yt osis of s urf a c e  Gl u A 2 r e c e pt ors ( Z h a n g et al. ,
2 0 1 1; Pr e n d er g ast et al. , 2 0 1 4)  w as p erf or m e d i n At a d 1 /
pri m ar y c orti c al n e ur o ns e x pr essi n g  G F P-t a g g e d  T h or as e
wil d-t y p e or  m ut a nt His 3 5 7 Ar gfs * 1 5 .  Li v e n e ur o ns  w er e i n c u-
b at e d  wit h a n a nti- Gl u A 2  N-t er mi n al a nti b o d y f oll o w e d b y
i n d u cti o n of  Gl u A 2 e n d o c yt osis  wit h  N M D A ( 2 0 m M) a n d
gl y ci n e ( 1 0 m M). I n c o ntr ol u nsti m ul at e d  T h or as e
m ut a nt His 3 5 7 Ar gfs * 1 5 c ult ur es t h er e  w as d e cr e as e d s urf a c e e x-
pr essi o n of  Gl u A 2 c o m p ar e d t o  T h or as e  wil d-t y p e c ult ur es
( Fi g. 4 E a n d F). I n c o ntr ast, t h e r ati o of s urf a c e  Gl u A 2/
i ntr a c ell ul ar  Gl u A 2 i n  N M D A- a n d gl y ci n e-sti m ul at e d
T h or as e  m ut a nt c orti c al c ult ur es r e m ai n e d si mil ar t o t h at
of sti m ul at e d  T h or as e  wil d-t y p e c ult ur es ( Fi g. 4 G a n d  H).
T h us, t h e  m ut a nt His 3 5 7 Ar gfs * 1 5 - e x pr essi n g n e ur o ns e x hi bit e d
si g ni Þ c a ntl y r e d u c e d s urf a c e  Gl u A 2 o nl y u n d er u nsti m ul at e d
c o n diti o ns.  T o f urt h er e v al u at e t h e eff e cts of t h e
p.( His 3 5 7 Ar gfs * 1 5)  m ut ati o n i n  T h or as e o n  A M P A R tr af-
Þ c ki n g,  Gl u A 2 s urf a c e e x pr essi o n  w as ass ess e d b y a bis(s ul-
f os u c ci ni mi d yl)-s u b er at e ( B S 3) cr oss-li n ki n g ass a y t h at all o ws
f or t h e q u a nti Þ c ati o n of b ot h s urf a c e a n d i ntr a c ell ul ar r e c e p-
t or p o ols ( C o nr a d et al. , 2 0 0 8).  T h e r es ults s u g g est e d
d e cr e as e d l e v els of s urf a c e  Gl u A 2 i n u nsti m ul at e d
m ut a nt His 3 5 7 Ar gfs * 1 5 - e x pr essi n g c ult ur es c o m p ar e d t o  wil d-
t y p e- e x pr essi n g c ult ur es ( Fi g. 4I a n d J). I n r es p o ns e t o
N M D A, t h er e  w as n o si g ni Þ c a nt diff er e n c e i n i nt er n ali z ati o n
of s urf a c e  Gl u A 2 i n t h e t w o c ult ur es ( Fi g. 4I a n d J).
T o g et h er, t h e d at a s u g g est t h at t h e  T h or as e
m ut a nt His 3 5 7 Ar gfs * 1 5 m a y i n hi bit t h e r e c y cli n g b a c k a n d/ or
Fi g u r e 3 T h e A T A D 1 m u t a ti o n p.( Hi s 3 5 7 A r gf s * 1 5) l e a d s t o r e d u c e d a m o u n t  of s o m e  mi t o c h o n d ri al p r o t ei n s i n p a ti e n t- d e ri v e d
fi b r o bl a s t s a n d l o c k s  T h o r a s e i n t h e  oli g o m e ri c s t a t e. (A ) I m m u n o bl ots of l ys at es o bt ai n e d f r o m p ati e nt a n d c o nt r ol Þ b r o bl asts.
C O X 4 = c yt o c h r o m e c o xi d as e s u b u nit 4;  H X K 1, = h e x o ki n as e 1; P E X 2 6 = p e r o xis o m al bi o g e n esis f a ct o r 2 6;  V D A C 1 = v olt a g e d e p e n d e nt a ni o n
c h a n n el 1. ( B )  O pti c al d e nsit o m et r y q u a nti Þ c ati o n of (A ).  Val u es r e p r es e nt t h e  m e a n + S E M (n = 3, P 5 0. 0 1, P 5 0. 0 5, P 5 0. 1 0, n.s. 4
0. 1 0, t w o- w a y  A N O V A,  Tu k e yÕs  m ulti pl e c o m p a ris o n t ests). ( C )  R e p r es e nt ati v e i m m u n o ß u o r es c e n c e i m a g es of t h e  mit o c h o n d ri al  m o r p h ol o g y
( T O M M 2 0 st ai ni n g) i n c o nt r ol a n d p ati e nt Þ b r o bl asts.  T h e c ells  w e r e als o st ai n e d f o r  G ol gi ( G O S 2 8), p e r o xis o m es ( P E X 2 6) a n d t h e n u cl ei  wit h
D A PI ( bl u e). ( D ) P r e di ct e d 3 D st r u ct u r e of  T h o r as e  wil d-t y p e ( g r e e n) a n d  m ut a nt His 3 5 7 A r gfs * 1 5 ( r e d). (E ) Si z e e x cl usi v e c h r o m at o g r a p h p r o Þl e of
p u ri Þ e d r e c o m bi n a nt  T h o r as e.  Wil d-t y p e  T h o r as e a p p e a rs as a di m e r ( 7 0 k D a),  w h e r e as t h e  T h o r as e  m ut a nt His 3 5 7 A r gfs * 1 5 a p p e a rs as oli g o m e r
(4 4 0 0 k D a). ( F ) P u ri Þ e d p r ot ei ns r es ol v e d o n 1 0 % S D S- P A G E st ai n e d  wit h c o o m assi e (l eft) a n d i m m u n o bl ott e d  wit h a nti- T h o r as e a nti b o d y
(ri g ht).

















































































Figure 2-2. The ATAD1 mutation p.(His357Argfs*15) leads to reduced amounts of 
some mitochondrial proteins in patient-derived fibroblasts. A, Immunoblots of 
lysates obtained from patient and control fibroblasts. COX4 = cytochrome c oxidase 
subunit 4; HXK1, = hexokinase 1; PEX26 = peroxisomal biogenesis factor 26; VDAC1 = 
voltage dependent anion channel 1. B, Optical densitometry quantification of (A). Values 
represent the mean +/- SEM (n = 3, ***P < 0.01, **P < 0.05, *P < 0.10, n.s. > 0.10, two-
way ANOVA, Tukey’s multiple comparison tests).
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Chapter 3. AAA+ ATPase Thorase Regulates mTOR 
Signaling Through the Disassembly of the mTOR 
Complex 1 
Introduction 
Thorase, also known as ATPase family AAA domain-containing protein 1 (ATAD1), 
belongs to the family of AAA+ ATPases associated with diverse cellular functions, 
which use energy garnered from ATP hydrolysis to disassemble protein complexes (Dai 
et al, 2010; Zhang et al, 2011). Thorase controls the endocytosis and internalization of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) through the 
disassembly of the AMPAR/glutamate receptor–interacting protein 1 (GRIP1) complex, 
thereby contributing to the regulation of synaptic plasticity, learning and memory (Zhang 
et al, 2011; Pignatelli et al, 2017; Umanah et al, 2017). Thorase also exerts an important 
function in maintaining mitochondrial and peroxisomal integrity by extracting 
mislocalized proteins out of these organelles (Chen et al, 2014; Okreglak et al, 2014; 
Prendergast et al, 2014). Recently, we have identified patients harboring Thorase 
mutations that suffer from a devastating neurological disease, with symptoms that include 
epilepsy in patients with loss-of-function mutations and aberrant or delayed myelination 
in patients with gain-of-function mutations (Umanah et al, 2017; Ahrens-Nicklas et al, 
2017; Piard et al, 2018; Wolf et al, 2018). 
 
Because Thorase abnormalities in humans show a broad clinical spectrum, and because 
Thorase belongs to a family of proteins known to perform multiple functions at a time, 
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we sought to discover novel roles for Thorase in the cell that could allow us to better 
understand its protective effects. For that, we decided to take an unbiased approach and 
search for novel Thorase interactors in the brain.  
 
Results 
Thorase interacts with mTOR kinase 
In a search for additional novel Thorase-interacting proteins, we used recombinant GST-
tagged Thorase to pull down potential Thorase interactors from whole brain lysates (Fig. 
3-1A). Among the putative Thorase binding partners, mass spectrometry identified the 
mTOR kinase (Fig. 3-1B, Fig. 3-5A). When separating protein complexes pulled down 
by recombinant Thorase from brain lysates according to their molecular size using fast 
protein liquid chromatography (FPLC), we confirmed via immunoblotting that 
endogenous mTOR and recombinant Thorase co-exist in complexes of high molecular 
weight (FPLC fractions 1-4 in Fig. 3-1C, FPLC fractions 2-3 in Fig. 3-5B). Thorase 
preferentially binds to mTOR, rather than mTORC1-associated proteins Raptor, S6K or 
4EBP1 (Fig. 3-5, C and D). Binding between Thorase and mTOR is direct, as revealed by 
our experiments performed in vitro, where purified recombinant mTOR and Thorase 
proteins alone assembled into high molecular weight complexes similar to those observed 
in vivo (Fig. 3-5E). Binding of Thorase and mTOR is strong in the presence of a non-
hydrolizable ATP analog (ATPgammaS), which generally enhances binding of Thorase 
to its substrates (Zhang et al, 2011; Umanah et al, 2017), both when we pull down 
endogenous Thorase (Fig. 3-5, C and D) or in the reverse pull down of endogenous 
mTOR (Fig. 3-1, D and E). Concomitant to a strong binding between Thorase to mTOR, 
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we detected a decrease in mTOR binding to the mTORC1 component Raptor, and 
mTORC1 substrates S6K and 4EBP1 (Fig. 3-1 D-F). In contrast, when we performed 
immunoprecipitation assays in the presence of hydrolizable ATP or ADP, both pull down 
of mTOR by Thorase and pull down of Thorase by mTOR was less efficient, as was the 
case with other Thorase interactors (Zhang et al, 2011; Umanah et al, 2017) (Fig. 3-1 D 
and E, Fig. 3-5 C and D). A weaker interaction between Thorase and mTOR in the 
presence of ADP or hydrolizable ATP correlated to an enhanced binding of mTOR to 
Raptor, 4EBP and S6 (Fig. 3-1 D-F). Moreover, in the absence of Thorase, Raptor, S6K 
and 4EBP1 proteins co-immunoprecipitated with mTOR regardless of what nucleotide 
we added to the reaction (Fig. 3-1, D-F). Overall, these results suggest that Thorase 
directly interacts with mTOR and that it may be involved in the disassembly of the 
mTORC1.  
 
Thorase disassembles the mTOR complex 1 
To further elucidate the molecular interaction between Thorase and the mTORC1, we 
used single-molecule pull-down (SiMPull), which combines traditional 
immunoprecipitation with single molecule fluorescence imaging, allowing for the study 
of the binding dynamics within protein complexes (Aggarwal and Ha, 2013; Jain et al, 
2011; Jain et al 2014). We pulled down mTORC1 on slides from cell extracts by 
capturing the mTORC1-specific protein Raptor tagged with red fluorescent protein 
(RFP), and imaged yellow fluorescent protein (YFP)-tagged mTOR and RFP-Raptor 
(Fig. 3-2A, Fig. 3-6A). The addition of recombinant Thorase led to a decrease in the 
number of mTOR molecules on the slide in a dose-dependent manner and with a mid-
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point Thorase concentration of 0.33 nM, consistent with a high avidity binding of 
Thorase to mTOR, resulting in its dissociation from Raptor and other mTORC1 
components (Fig. 3-2 B and C, Fig. 3-6 C and D). There was no significant change in the 
number of RFP-Raptor spots after the addition of Thorase (Fig. 3-2B, Fig. 3-6 C and D), 
and Thorase did not disassemble the PKA complex that was used as a control (Jain et al, 
2011) (Figs. 3-6, B, E and F). When we pulled down mTORC1 on slides via the capture 
of YFP-mTOR and added Cy5-labeled Thorase (Fig. 3-6G), the number of RFP-Raptor 
spots decreased while the number of Cy5-Thorase spots increased, suggesting that 
Thorase displaces Raptor and binds to mTOR (Fig. 3-6, H and upper panels on I). When 
pulling down mTORC1 via capture of Raptor or in the control experiments with the PKA 
complex, a significantly smaller number of Cy5-Thorase molecules were detected bound 
to Raptor or the PKA complex, respectively (Fig. 3-6, lower panels on I and J), 
supportive of the specificity of binding of Thorase to mTOR. mTOR disassembly from 
Raptor by Thorase is dependent on ATP binding, as addition of Thorase in the presence 
of the non-hydrolyzable ATP analog AMP-PNP promoted a significantly sharper 
decrease of YFP-mTOR and RFP-Raptor spots, compared to Thorase addition in the 
presence of ADP or ATP (Fig. 3-7, A-F). Similarly, the efficiency of disassembly of 
mTOR, as measured by disappearance of YFP-mTOR spots, decreased in the presence of 
Thorase mutants Walker A and Walker AB that are incapable of binding ATP, as 
compared to wild type Thorase or mutant Walker B which can bind ATP but not 
hydrolyze it (Zhang et al, 2011) (Fig. 3-7, G and H). In the absence of Thorase, the dimer 
forms of mTOR and Raptor were the dominant species (Aggarwal and Ha, 2013; Jain et 
al, 2011; Jain et al 2014), whereas monomeric mTOR and Raptor emerged as the 
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dominant species following Thorase addition (Fig. 3-7, C, F and I). Detailed 
stoichiometric analyses of the mTORC1 further confirms that the dimeric species, 
mT2R2, dominates in the absence of Thorase, whereas the monomeric species, mT1R1, 
dominates in the presence of Thorase (Fig. 3-2 D-E, Fig. 3-7J). This suggests that 
Thorase disassembles the mTORC1 by removing mTOR molecules one at a time (Fig. 3-
2 D-E, Fig. 3-7 C, F, I and J). To determine the binding site of mTOR in Thorase, we 
generated N-terminal (N40, N50, N60, N70, N90, N100) and C-terminal (C10 and C20) 
truncated variants (Fig. 3-8A). GST-Thorase and mTOR pulldown analyses suggest that 
deletion of the residues 70-90 inhibits the binding of mTOR to Thorase (Fig. 3-8, B-E). 
SiMPull analyses confirm that the N-terminus of Thorase is critical for binding to mTOR, 
since mutants lacking the first hundred amino acid residues of Thorase disassemble the 
mTOR-Raptor complex less efficiently (Fig. 3-8, F-G). Collectively, these findings show 
that Thorase binds strongly to mTOR to mediate the disassembly of the mTORC1. 
 
Lack of Thorase results in excessive mTORC1 activity in vitro and in vivo 
To verify that mTOR is a substrate of Thorase in vivo, we analyzed the status of the 
mTOR signaling pathway in the brains of mice lacking Thorase. The total and 
phosphorylated levels of several mTORC1-related proteins were increased in the cortices 
and hippocampi of Thorase knockout mice, suggesting that elevated mTORC1 signaling 
occurs in the absence of Thorase (Fig. 3-3 A-C, Fig. 3-9 A and B). Consistent with 
upregulated mTORC1 signaling, we found an increased abundance of poly-ubiquitinated 
proteins in the brains of Thorase knockout mice (Fig. 3-3, D and E). We confirmed the 
same mTORC1 hyperactivity occurs in fibroblasts derived from Thorase knockout mouse 
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embryos, which presented increased levels of mTORC1 signaling (Fig. 3-9, C and D) and 
consequent increased amounts of newly-synthesized proteins (Fig. 3-9, E and F).  
Next, we sought to determine whether the absence of Thorase and subsequent 
dysregulation of mTORC1 disassembly may have any physiological consequences. 
mTORC1 activity is central to regulating oligodendrocyte differentiation and myelination 
(Zou et al, 2011). We found that the levels of myelin and oligodendrocyte markers CNP, 
MBP, TMEM10 and MOG were higher in both the cortices and hippocampi of mice 
lacking Thorase (Fig. 3-4, A and B). We could also detect higher levels of myelin 
through black gold staining in the brains of Thorase knockout mice, as well as increased 
levels of MBP and TMEM10 in axon fibers (Fig. 3-4, C and E) which also appeared more 
compact (Fig. 3-10A). The numbers of mature oligodendrocytes, which can be identified 
by double staining with Olig2 and CC1, were higher in the absence of Thorase, and this 
may account for the increased levels of myelin observed (Fig. 3-4 D and E, Fig. 3-10B). 
Accordingly, the myelin sheath of axons in the optic nerve appeared significantly thicker 
under transmission electron microscopy in the absence of Thorase (Fig. 3-4F, Figs. 3-10 
C-F) and, consequently, the g ratio (or ratio of the inner diameter to the total outer 
diameter of myelinated axons) was smaller in the optic nerves of Thorase knockout mice 
(Fig. 3-4G).  Furthermore, Thorase knockout mice present a non-significant increase in 
the number of myelinated axons (Fig. 3-4H). These results support the idea that the 
absence of Thorase results in sustained mTORC1 activity, with subsequent alteration of 
the physiological processes downstream of mTORC1 signaling, including increased 
myelination in the optic nerve.  
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Rapamycin can alleviate the mTORC1 hyperactivity observed in the absence of 
Thorase 
Lastly, we tested whether the mTOR inhibitor, rapamycin, could alleviate the mTORC1 
hyperactivity observed when Thorase is lacking. Indeed, the levels of phosphorylated S6 
in fibroblasts derived from either Thorase knockout mice or wild type littermates 
decreased significantly after the treatment with rapamycin as compared to vehicle-treated 
counterparts, with phosphorylated S6 levels equally as low in rapamycin-treated wildtype 
and Thorase knockout fibroblasts (Fig. 3-4, I and J).  In contrast, the levels of the 
rapamycin-resistant T37/46 site in 4EBP did not significantly change in either wildtype 
or Thorase knockout fibroblasts treated with rapamycin (Fig. 3-4, I and J).  Consequent to 
the rapamycin treatment, the synthesis of new proteins in these fibroblasts as measured 
by incorporation of radiolabeled methionine was decreased as well (Fig. 3-4, K and L). 
Thorase knockout mice have a very short lifespan, with most mice dying three weeks 
after birth, due to epileptic seizures (Zhang et al, 2011). To test whether mTORC1 
hyperactivity may be accountable for the pathology underlying the sudden death of 
Thorase knockout mice, we treated mice with rapamycin. Decreasing mTOR activity 
with rapamycin lengthened the lifespan of mice lacking Thorase, with a significant 
increase in their median survival compared to vehicle-treated Thorase knockout mice 
(Fig. 3-4M). Some mice doubled their life span, surviving for over 60 days postnatally, 
compared to vehicle-treated knockout littermates (Fig. 3-4M). These results taken 
together indicate that, in mice lacking Thorase, mTOR activity is increased and this 




In summary, we have found that AAA+ ATPase Thorase serves as a molecular motor that 
disassembles the mTORC1, which is central to attenuating its downstream signaling 
activity. By directly binding to mTOR, Thorase prevents its binding to other mTORC1 
components. In the absence of Thorase, mTORC1 signaling is hyperactive, leading to the 
dysregulation of several processes downstream of mTORC1 signaling, such as de novo 
protein synthesis at a cellular level, or myelination of axons in the brain physiologically. 
The regulation of mTORC1 activity by Thorase may also be relevant to human disease, 
as we have identified patients harboring Thorase mutations that suffer from a devastating 
neurological disease, with symptoms that include epilepsy in patients with loss-of-
function mutations and aberrant or delayed myelination in patients with gain-of-function 
mutations. Deregulation of the mTOR signaling pathway underpins numerous human 
diseases, including epilepsy (Crino, 2015). Overall, our discovery that Thorase is a novel 
modulator of mTOR activity that acts through the disassembly of the mTORC1 sheds 
some light onto how the pathway is terminated and provides a potential new therapeutic 
avenue to treat the myriad of human diseases related to dysregulated mTOR signaling.  
 
Material and Methods 
Antibodies and chemicals 
We purchased anti-Thorase (NeuroMab Cat# 75-157 RRID:AB_2290002) from UC 
Davis/NIH NeuroMab facility. Primary antibodies for mTOR (#2983), phos-S2448 
mTOR (#5536), phos- S2481 mTOR (#2974), Raptor (#2280), phos-S792 Raptor 
(#2083), anti-Rictor (#2114), phos- T1135 Rictor (#3806), p70 S6K (#2708), phos-T389 
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p70 S6K- (#9205), anti-S6 (#2217), phos- S240/244 S6 (#2215), 4EBP1 (#9644), phos-
T37/46 4EBP1 (#2855), elF4B (#3592), phos-S422 elF4B (#3591), ULK1 (#8054), phos-
S757 ULK1 (#6888), Rheb1 (#13879) were purchased from Cell Signaling Technologies. 
Antibodies for Tomm20 (#ab186735), anti-rabbit (#ab98467) and anti-mouse (#ab6823) 
were purchased from Abcam. Anti-rabbit Alexa Fluor®647 Conjugate (#A32733), anti-
mouse Alexa Fluor®594 Conjugate (#A11032) and Anti-rabbit Alexa Fluor®488 
Conjugate (#A32731) secondary antibodies were purchased from Invitrogen. Anti-CC1 
and anti- MBP antibodies were purchased from Calbiochem (San Diego, CA); anti-Olig2 
antibody from Millipore (Billerica, MA). Tmem10 antibody was generated by 
immunizing New Zealand white rabbits with bacterial His-tagged fusion protein. Black 
Gold II Myelin Staining Kit was purchased from Millipore. All antibodies used for 
SiMPull were obtained from commercial sources as follows: biotinylated anti-RFP from 
Abcam (ab34771) and anti-YFP from Rockland Antibodies and Assays. DAPI was 
purchased from Invitrogen (Molecular Probes). Hank’s balanced salt solution (HBSS) 
(#14025), Neurobasal (#21103049), Dulbecco's Modified Eagle Medium (DMEM) 
(#11995), Fetal Bovine Serum (FBS) (#16140071), and B-27 supplement (#17504044) 
were purchased from Gibco. L-Glutamine (#25-005-CI) and Penicillin-Streptomycin 
(#30-002-CI) were purchased from Corning. Poly-L-ornithine hydrobromide (#P3655-
1G) was purchased from Sigma Aldrich. 
 
Other reagents include Prescission Protease (#27-0843-01 GE Healthcare), ATPgammaS, 
Adenosine 5’- (3-thiotriphosphate) tetralithium salt (A1388-25MG MilliporeSigma) 
Nickel-NTA (Qiagen), glutathione beads (#SKU 16101 Pierce), QuickChange site-
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directed mutagenesis kit (Stratagene, USA), E. coli BL21(DE3) RIL cells (E. coli 
BL21(DE3) RIL cells (#69450 Novagen), Neutravidin (#31000 Thermo Fisher) and BSA 
(#B9000S New England Biolabs). 
 
Plasmids 
Thorase was cloned into lenti-viral plasmid pLVX-IRES-mCherry (Thorase, Ires 
Mcherry), the AAV-viral plasmid pAM/CBA-pl-WPRE-BGH, with FLAG epitope tag 
(Thorase-FLAG) and lenti-viral cFUGW plasmid (Thorase-GFP) vectors. Thorase coding 
sequence was inserted into pLVX-IRES-mCherry (Clontech, USA) or pAM/CBA-pl-
WPRE-BGH between XhoI and BamHI and into cFUGW vector between BamHI and 
AgeI sites. These plasmids were used for Thorase expression in HEK293 cells, mouse 
embryonic fibroblasts (MEFs), or primary neurons. Thorase was also cloned into 
pGEX6P-1 (Addgene) and pET32a (Novagen) vectors (BamHI and XhoI sites) and were 
expressed as GST and His6 fusion recombinant proteins, respectively. Site directed PCR 
and restriction enzyme digest were performed to generate Thorase truncated variants, 
N30, N40, N50, N60, N70, N90, N100 which have the first 30, 40, 50, 60, 70, 90 and 100 
residues deleted, respectively. Thorase deletion variants, C10 and C20 with the last 10 
and 20 residues deleted, respectively, were also generated. GST-tagged mTOR was 
generated by inserting the full-length coding sequence at the NotI site in pGEX6P-1. All 
plasmids constructs were verified by sequencing at The Johns Hopkins University DNA 
sequencing facility. Lamp1-RFP plasmid was commercially obtained from Addgene 
(Plasmid #1817). All plasmids used for SiMPull were obtained from commercial sources 
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as follows: peYFP-C1-mTOR (Addgene Plasmid #73384) and pRK5-HA-mCherry-
Raptor (Addgene Plasmid #73386). 
 
Lentivirus Generation 
Lentiviruses expressing Thorase were generated by the transient transfection of 
HEK293T cells with lentiviral plasmids described above using FuGENE HD 
Transfection Reagent (Roche Applied Science). The cells were co-transfected with the 
Thorase lentiviral plasmids, the transcomplementation plasmids (pLP1 and pLP2), and 
the plasmid encoding the vesicular stomatitis virus envelope glycoprotein (VSVG) 
followed by sodium butyrate treatment 6 hours after transfection. The medium was 
replaced 24 hours after transfection. Viral particles were harvested by collecting medium 
48 hours and 72 hours after transfection and centrifuged at 3000g for 10 minutes, then 
filtered through a 0.45 um membrane. Viral particles were then concentrated by 
ultracentrifugation (2 hours, 25,000 rpm, rotor SW28). The viruses were stored at -80oC 
until needed. The expression of Thorase was verified by infecting HEK293 cells with 
viruses and cells examined under fluorescence microscope 24-48 hours after infection. 
Cells were harvested and lysates were resolved on SDS-PAGE and immunoblotted by 
probing with anti-Thorase. 
 
Recombinant protein purification 
GST- tagged fusion proteins were expressed in Escherichia coli strain BL21-CodonPlus 
(DE3)- RIPL (Stratagene, Agilent Tech. Div., USA) bacteria. Small cultures (100 ml) 
were grown overnight at 37oC and then transferred to 2 liter cultures for another 8 hours. 
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Cells were cold shocked at 4oC for 1 hour before adding 1mM IPTG for overnight 
induction at 16oC. Cells were lysed using micro-Fluidizer in binding buffer (1x phosphate 
buffer, pH 7.5, 150 mM NaCl, 2.5 mM MgCl2, 1 mM DTT, 5% glycerol) containing 
protease inhibitors and purified by using GST beads (GE Healthcare) following the 
manufacturer’s instructions. To obtain untagged purified proteins, GST-tagged proteins 
bound to the GST beads were treated with Prescission protease (GE Healthcare) to 
remove the GST tags. Samples were further purified using ion 5 exchange 
chromatography and/or size-exclusion chromatography. Purity of the recombinant 
proteins was assessed by SDS-PAGE followed by Coomassie blue staining and 
immunoblotting. 
 
Pull down assays 
For the identification of Thorase binding partners, recombinant GST-Thorase purified on 
beads was mixed with mouse whole brain lysates in the presence of non-hydrolysable 
ATP (ATPgammaS) in buffer A (50 mM HEPES, pH 7.5, 150 mM NaCl, 2.5 mM 
MgCl2, 1 mM DTT, 5% glycerol) and incubated with end-over-end mixing for 2 hours. 
The beads were then extensively washed with buffer A containing ATPgammaS, and 
Thorase was cleaved from the GST beads with PreScission protease (GE Healthcare). 
The supernatant containing different protein complexes bound to Thorase was loaded into 
size-exclusion chromatography to separate the complexes. The different fractions eluted 
from the column were resolved by SDS-PAGE and individual bands (proteins) were 
excised for mass spectrometry analyses. Immunoblotting was used to confirm the 
presence of proteins identified by mass spectrometry.  
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Co-immunoprecipitation of endogenous Thorase and mTOR was carried out using lysates 
of whole mouse brains. Freshly isolated whole brains from wildtype or Thorase knockout 
mice were powderized under dry ice and homogenized in buffer A containing protease 
inhibitors with or without 2 mM ADP, ATP or ATPgammaS. Triton X-100 was added to 
a final concentration of 1% followed by rotation for 2 hours at 4oC. Extracts were 
centrifuged at 15,000g for 30 minutes and supernatant was incubated for 3 hours at 4oC 
with Protein G beads (Pierce) pre-bound with anti- Thorase or anti-mTOR antibodies. 
The beads were washed 3 times with buffer A plus 1 mM ADP, ATP or ATPgammaS 
and bound proteins were eluted from beads using 1x SDS-PAGE Laemmli buffer (Sigma) 
with DTT. The eluted proteins were resolved by SDS-PAGE. Immunoblotting analyzes 
were carried out with antibodies to Thorase, mTOR, Raptor, S6K and 4EBP1. 
 
For in vitro pull down of Thorase and mTOR, recombinant GST-Thorase (wildtype or 
variants) or GST-mTOR purified on beads were mixed with mouse whole brain lysates in 
the presence of 2 mM ADP, ATP or ATPgammaS in buffer A and incubated with mixing 
for 2 hours. The beads were then extensively washed with buffer A containing 1 mM 
ADP, ATP or ATPgammaS. The beads were resuspended in 1 x SDS-PAGE sample 
buffer and eluted samples resolved by SDS-PAGE. Immunoblotting was used to confirm 
the presence of proteins bound to GST-tagged proteins. For assessing direct interaction 
between Thorase and mTOR, recombinant GST-Thorase purified on beads was mixed 
with purified non-tagged mTOR recombinant protein in the presence of 2 mM 
ATPgammaS in buffer A and incubated with mixing for 2 hours. The beads were then 
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extensively washed with buffer A containing 1 mM ATPgammaS. The sample eluted 
from the beads was loaded into sizeexclusion chromatography to separate the complexes. 
The different fractions eluted from the column were resolved by SDS-PAGE to confirm 
the presence of GST-Thorase and mTOR. Mass spectrometry was conducted at Harvard 
Medical School Taplin Spectrometry Facility. 
 
Cell Culture 
HEK293 and MEFs were maintained in at 37oC with a 5% CO2 atmosphere in a 
humidified incubator, and grown in DMEM supplemented with 10% FBS and 1% PS. 
Transfections in HEK293 were performed with Lipofectamine 2000 Reagent (Invitrogen) 
according to the manufacturer's instructions.  
 
Primary cortical neuron cultures were prepared from embryonic day 15 (E15) mouse 
pups and grown in Neurobasal media (Gibco) with B27 supplement (Gibco), 1% L-
glutamine and 1% PS (complete neurobasal media), and maintained in at 37oC with a 7% 
CO2 atmosphere in a humidified incubator. 
 
De novo protein synthesis assessment 
Fibroblasts derived from wildtype or Thorase knockout mouse embryos were grown in 12 
well plates (Falcon) to around 80% confluency, and pre-treated with vehicle DMSO or 
500 nM rapamycin (LC laboratories) if needed. 25 uCi of 35S-L-methionine/35S-L-
cysteine (PerkinElmer) per well were added to the media, and cells were incubated at 
37oC and 5% CO2 for 1 hour. Cells were then washed twice with cold PBS, and lysed in 
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extraction buffer (2% NP-40, 50 mM Tris HCl, 150 mM NaCl, 5 mM EGTA, protease 
inhibitor cocktail), spun down and supernatants collected. Protein was concentrated with 
methanol/heparin, and protein pellets then resuspended in 8M Urea/150 mM Tris (pH 
8.5). Samples were then analyzed in a LS 6500 Multi-purpose 9 Scintillation Counter 
(Beckman Coulter), and radioactive counts normalized to sample protein concentration as 
measured by Pierce BCA protein assay (Thermo Scientific). 
 
Myelination studies 
For immunohistochemistry experiments, mouse brains were prepared by cardiac 
perfusion and stained as described above. Black Gold staining (Millipore) was performed 
following the manufacturer’s instructions. For optic nerve myelination analysis through 
electron microscopy, animals were perfused with 2% glutaraldehyde 2% 
paraformaldehyde (freshly prepared from EM-grade prill) 75 mM sodium cacodylate 75 
mM phosphate (Sorenson’s) 3 mM MgCl2, pH 7.2 at 1006 mOmols. After perfusion, 
animals were kept at 4oC for two hours, then brains and optic nerves were carefully 
removed and placed in fresh fixative overnight at 4oC. The following steps were kept 
cold (4oC) until the 70% ethanol step, then run at room temperature. Samples were rinsed 
in 75 mM cacodylate 75 mM phosphate 3.5% sucrose MgCl2, pH 7.2 at 442 mOsmols 
for 45 min. Following buffer rinses, samples were post-fixed in 2% osmium tetroxide 
reduced with 1.6% potassium ferrocyanide, in the same buffer without sucrose for 2 
hours on ice in the dark. Optic nerves were then rinsed in 100 mM maleate buffer with 
3.5% sucrose pH 6.2, then en-bloc stained for 1 hour with filtered 2% uranyl acetate in 
maleate sucrose buffer, pH 6.2. Following en-bloc staining samples were dehydrated 
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through a graded series of ethanol to 100%, transferred through propylene oxide, 
embedded in Eponate 12 (Pella) and cured at 60 oC for two days. Sections were cut on a 
Riechert Ultracut E microtome with a Diatome Diamond knife (45 degree). 60nm 
sections were picked up on formvar coated 1 x 2 mm copper slot grids and stained with 
methanolic uranyl acetate followed by lead citrate. Grids were viewed on a Hitachi 7600 




HEK293 cells were transiently co-transfected with YFP-mTOR and mCherry-Raptor 
followed by cell lysis in lysis buffer (40 mM Hepes, pH 7.5, 120 mM NaCl, 10 mM 
sodium pyrophosphate, 10 mM b-glycerophosphate, 1X protease inhibitor mixture and 
0.3% CHAPS). YFP-mTOR- and mCherry-Raptor-only lysates were obtained by 
transiently transfecting cells with YFP-mTOR and mCherry-Raptor, respectively. Lysates 
were centrifuged at 12,000 X g for 12 min at 4oC and diluted 150-fold to obtain a surface 
density optimal for single-molecule analysis (~800 molecules in 5,000 μm2 imaging 
area). For control experiments, HEK293 cells were transiently transfected with PKA 
isoforms PKA-RIIb-Flag-mCherry and PKA-Ca-HA-YFP. After 24 hours of expression, 
cells were lysed using a buffer containing 10mM Tris pH 7.5, 1% NP-40, 150 mM NaCl, 
1 mM EDTA, 1 mM benzamidine, 10 μg/ml leupeptin, 1mM NaF, 1mM Na3VO4. The 




Recombinant Thorase was incubated with 20-fold molar excess of Cy5-maleimide dye 
(GE Healthcare Life Sciences) in 1X PBS buffer (Thermo Fisher Scientific) at room 
temperature for an hour and at 4oC overnight. Unreacted dyes were removed by gel 
filtration using Zeba spin desalting columns (7K MWCO, Thermo Fisher Scientific). 
Single-molecule experiments were performed on a prism-type TIRF microscope 
equipped with an electron-multiplying CCD camera (EM-CCD). For single-molecule 
pull-down experiments, quartz slides and glass cover slips were passivated with 5000 
MW methoxy poly-(ethylene glycol) (mPEG, Laysan Bio) doped with 2-5% 5000 MW 
biotinylated PEG (Laysan Bio). Cell lysates were pulled down with biotinylated 
antibodies against YFP or RFP, already immobilized on the surface via neutravidin-biotin 
linkage. Thorase interactions with mTORC1 and its individual components were studied 
by incubation of pulled-down mTORC1 or its individual components with a pre-
determined concentration of Cy5-Thorase in T200-BSA buffer supplemented with 5 mM 
AMP-PNP (or ATP, Sigma-Aldrich), 20 mM MgCl2 and 10% Glycerol. 15 frames were 
recorded from each of 20 different imaging areas (5,000 μm2) and isolated single-
molecule peaks were identified by fitting a Gaussian profile to the average intensity from 
the first ten frames. Mean spot-count per image for YFP and mCherry was obtained by 
averaging 20 imaging areas using MATLAB scripts. 
 
Co-localization data were acquired from two or three separate movies from the same 
region of a slide using YFP, m-Cherry and Cy5 excitation. The co-localization criterion 
was set to a diffraction limited region of ~300 nm, which corresponds to 2 pixels for this 
TIRF setup. % co-localization was calculated as the % molecules co-aligned with the 
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pulled down component, unless otherwise stated. YFP, mCherry and Cy5 images taken 
from different areas were also overlapped to determine the probability of false co-
localization arising from random spatial overlap of single molecules. Average % co-
localization was calculated based on a minimum of 30 individual slide areas. 
 
For photobleaching analysis, single-molecule fluorescent time traces from individual 
YFP or mCherry spots were manually scored for the number of photobleaching steps and 
the stoichiometry of the molecules was assessed subsequently as described before. 
 
Animals 
Thorase homozygous knockout mice and wildtype littermates were obtained by crossing 
heterozygous Thorase mice. Animal experiments were performed in compliance with the 
regulations of the Animal Ethical Committee of the Johns Hopkins University Animal 
Care and Use Committee. 
 
Rapamycin treatment in mice 
Wildtype or Thorase knockout mice were injected intraperitoneally with 6mk/kg 
Rapamycin (#R- 5000, LC laboratories) or vehicle (10% PEG400, 10% Tween 80 in 
water), 3 times per week starting at 10-14 days postnatally. 
 
Study design and reproducibility 
All biochemical and imaging experiments were repeated independently at least three 
times. For biochemical experiments involving brain tissue or mouse embryonic 
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fibroblasts, 3 biological replicates per group were used per experiment. For mouse 
survival experiments and immunohistochemical analysis, enough sample size (as 
determined via post hoc power analysis) was used, and mice pertaining to different litters 
were used. For biochemical experiments where 2 treatments were applied, 2 technical 
replicates per biological sample (3 biological replicates total per group) were used. We 
found our results reproducible when experiments were performed by 2 independent 
researchers. For mouse experiments where either vehicle or rapamycin was injected, an 
independent researcher randomly allocated mice to either treatment group. Regarding 
blinding during data collection, for immunofluorescence, immunohistochemistry and 
electron microscopy imaging, researchers were blinded to genotypes. For mouse survival 
analysis, researchers were blinded to both genotype and treatment groups. 
 
Data analysis and statistics 
All experiments were repeated at least three times and quantitative data are presented as 
the mean ± standard error of the mean (SEM) by GraphPad prism6 software (Instat, 
GraphPad Software). Statistical significance was assessed by ANOVA. The significant 
differences were identified by post-hoc analysis using the Tukey-Kramer post-hoc 
method for multiple comparisons. Assessments were considered significant with a p < 
0.05 and non-significant with a p > 0.05. To assess the sufficiency of sample size, post 
hoc power analysis was performed, considering a power greater than 0.9 sufficient. 
Power analysis and sample size calculation for all experiments were determined using 
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Figure 3-1. Thorase interaction with mTOR is concomitant to a decrease in binding 





Figure 3-1. Thorase interaction with mTOR is concomitant to a decrease in binding 
of mTOR to other mTOR complex 1-related proteins. A, Schematic diagram of 
recombinant Thorase pulldown from brain lysates to identify novel binding partners 
through mass spectrometry. B, Representative mTOR peptide fragmentation detected by 
mass spectrometry after Thorase pulldowns. C, SDS-PAGE and immunoblots of FPLC 
fractions of Thorase pulldown of mTOR. D, Immunoblot images of mTOR pulldown 
from wildtype (WT) or Thorase knockout (KO) brain lysates in the presence of different 
nucleotides. E, Quantification of blots in D (n = 3). F, Graphical representation of percent 
disassembly of mTORC1-related proteins in D (n = 3). Data in E and F are mean ± 
standard error of the mean [SEM] of three independent experiments, ***p < 0.001, *p < 












Figure 3-2. Thorase disassembles the mTOR complex 1. A, Schematic depiction of 
mTORC1 SiMPull in the presence of Thorase. B, Representative images from SiMPull 
shown in A with different concentrations of Thorase. C, Graphical representation of the 
kinetics of Thorase disassembly of mTOR-Raptor complex with a Kd value of 0.33 nM. 
D, Schematic diagram of SiMPull showing how Thorase disassembles mTOR-Raptor 
complex. E, Graphical representation showing the distribution of the different mTOR-
Raptor species over time in the presence of Thorase (n = 3).
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Figure 3-3. Thorase regulates the activity levels of the mTORC1 pathway. A, 
Immunoblot images of mTORC1-associated proteins in wildtype (WT) and Thorase 
knockout (KO) mouse brains. B, Quantification of samples from the cortex (CTX) in a (n 
= 3). C, Quantification of samples from the hippocampus (HIPP) in a (n = 3). D, 
Representative immunoblot images showing increased levels of poly-ubiquitinated (FK1) 
proteins in Thorase KO mice. E, Quantification of blots in D (n = 4).
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Figure 3-4. Myelination levels are higher in Thorase knockout mice, and the mTOR 
inhibitor, rapamycin, ameliorates the phenotypes arising from the increased 













Figure 3-4. Myelination levels are higher in Thorase knockout mice, and the mTOR 
inhibitor, rapamycin, ameliorates the phenotypes arising from the increased 
mTORC1 activation observed in the absence of Thorase. A, Immunoblot images of 
myelin proteins and oligodendrocyte markers in wildtype (WT) and Thorase knockout 
(KO) mouse brain lysates. B, Quantification of blots in a (n = 3). C, Representative images 
of myelin proteins, MBP, TMEM10 and black gold staining in mouse brain sections (fibers 
indicated by red arrows). D, Representative images of oligodendrocyte olig2/CC1 staining 
in mouse brain sections (double positive cells indicated by white arrows). E, Quantification 
of staining intensities of images from C and D (n = 6). F, Representative images of 
myelinated axons in the optic nerves. G, Graphical representation of myelin thickness (g 
ratio) of the optic nerves (n = 15). H, Quantification of number of myelinated axons (n = 
15). I, Immunoblot images showing rapamycin (Rapa) treatment normalizes elevated 
mTORC1 activity in KO cells. J, Quantification of blots in I (n = 5). K, Representative 
images showing rapamycin inhibits increased protein synthesis in KO cells. L, 
Quantification of blots in J (n = 3). M, Survival curve of mice treated with rapamycin or 
vehicle (Veh) (Log Rank Mantel-Cox test, WT Veh n=12 ; WT Rapa n=9 ; KO Veh n=9 ; 
KO Rapa n=10; median survival KO Veh 24 days, KO Rapa 36 days). Data in B, E, G, H, 
J, L, M are mean ± standard error of the mean [SEM] of experiments performed, ****p < 
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, n.s p > 0.05, ANOVA with Tukey-Kramer 




Figure 3-5. Thorase interaction with mTOR is concomitant to a decrease in binding 





Figure 3-5. Thorase interaction with mTOR is concomitant to a decrease in binding 
of mTOR to other mTORC1-related proteins (part II). A, A list of mTOR peptides 
identified by mass spectrometry in Thorase pulldown. B, Immunoblots of FPLC fractions 
Thorase pulldown of mTOR. C, Immunoblot images of immunoprecipitation (IP) of 
Thorase in the presence of different nucleotides to pulldown mTORC1-associated 
proteins. D, Graphical representation of quantified blots in C (n = 3). E, Images of SDS-
PAGE of FPLC fractions and FPLC profile confirming direct interaction of purified 
recombinant mTOR and GST-Thorase complex on FPLC size-exclusive column. Data in 
D are mean ± standard error of the mean [SEM] of experiments performed, ***p < 0.001, 
*p < 0.05, n.s p > 0.05, ANOVA with Tukey-Kramer post-hoc test compared with ADP. 
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Figure 3-6. Thorase disassembles the mTOR complex 1 (part II). A, Schematic 
diagram of SiMPull analyses of mTOR-Raptor complex in the presence of Thorase. B, 
Schematic diagram of SiMPull analyses of PKA complex (control) in the presence of 
Thorase. C, Representative images from mTORC1 SiMPull confirming Thorase 
disassembles the mTOR-Raptor complex. D, Quantification of images in C (n = 3). E, 
Representative images from PKA SiMPull showing no significant disassembly of the 
control PKA complex in the presence of Thorase. F, Quantification of images in E (n = 
3). G, Schematic diagram of mTOR-Pulldown SiMPull showing Thorase binds to mTOR 
upon disassembly of Raptor from mTORC1. H, Graphical representation of Raptor (red) 
disassociation from mTOR and Thorase (blue) binding to mTOR over time (n = 3, 
Thorase-Cy5 values 5x). I, Representative images of SiMPull binding analyses showing 
that Thorase has higher affinity for mTOR than Raptor. J, Graphical representation of 
quantified intensities from images in I. Data in D, F, H, J are mean ± standard error of the 
mean [SEM] of experiments performed, ****p < 0.0001, ***p < 0.001, *p < 0.05, n.s p > 
0.05, ANOVA with Tukey-Kramer post-hoc test compared with control (no Thorase).
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Figure 3-7. Thorase disassembly of the mTORC1 is ATP dependent. A, Schematic 
diagram and representative images of Raptor-pulldown SiMPull analyses of mTOR-
Raptor complex in the presence of Thorase and different nucleotides. B, Quantification of 
number of mTOR spots per imaging area in a (n = 3). C, Quantification of the amount of 
different species of mTOR in the presence of Thorase and different nucleotides (n = 3). 
D, Schematic diagram and representative images of mTOR-pulldown SiMPull analyses 
of mTOR-Raptor complex in the presence of Thorase and different nucleotides. E, 
Quantification of number of Raptor spots per imaging area in D (n = 3). F, Quantification 
of the amount of different species of Raptor in the presence of Thorase and different 
nucleotides (n = 3). G, Schematic diagram and representative images of SiMPull analyses 
of mTOR-Raptor complex in the presence of different Thorase ATPase variants. 
H, Quantification of images in g showing Thorase ATP binding deficient variants, 
Walker A and AB do not significantly disassemble mTORC1 (n = 3). I, Graphical 
representation of the disassembly of different species of mTOR and Raptor in the 
presence of different concentrations of Thorase (n = 3). J, Schematic diagram and 
graphical representation of different complexes of mTORC1 in the presence of different 
concentrations of Thorase. Data in B, C, E, F, H, I, J are mean ± standard error of the 
mean [SEM] of experiments performed, ***p < 0.001, **p < 0.01, *p < 0.05, n.s p > 
0.05, ANOVA with Tukey-Kramer post-hoc test compared with wildtype or control (no 
Thorase).
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Figure 3-8. Thorase N-terminus is important for lysosomal localization. Fig. S4. 
Thorase N-terminus is essential for the interaction with mTOR. A, A schematic 
diagram of truncated variants of Thorase. B, Immunoblot images of different GST-
Thorase truncated variants pulldown of mTOR. C, Quantification of blots in B (n = 3). D, 
Immunoblot images of mTOR pulldown of different Thorase truncated variants. E, 
Quantification of blots in D (n = 3). F, Representative images from Raptor-pulldown 
SiMPull in the presence of Thorase truncated variants. G, Quantification of signal 
intensities of images in f (n = 3). Data in C, E, G are mean ± standard error of the mean 
[SEM] of experiments performed, ***p < 0.001, **p < 0.01, *p < 0.05, n.s p > 0.05, 
ANOVA with Tukey-Kramer post-hoc test compared with WT. 
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Figure 3-9. mTORC1-related protein levels are elevated in Thorase knockout mice 
and fibroblasts. A, Immunoblot images of mTORC1 protein expression in brain lysates 
of wildtype (WT) and Thorase knockout (KO) mice. B, Graphical representation of 
quantified blots in a (n = 3). C, Representative immunoblots mTORC1 protein expression 
in WT and KO mouse embryonic fibroblasts (MEFs). D, Quantification of blots in C (n = 
3). E, Representative images showing increased protein synthesis in KO MEFs compared 
to WT MEFs. F, Graphical representation of blots in E (n = 3). Data in B, D, F are mean 
± standard error of the mean [SEM] of experiments performed, ***p < 0.001, *p < 0.05, 









Figure 3-10. Increased myelination in Thorase knockout mice. A, Representative 
images of myelin basic protein (MBP) staining of different regions of the brain of 
wildtype (WT) and Thorase knockout (KO) mice. Increased myelin fibers in the cortex 
frontoparietalis as well as high levels of compact myelin fibers in the caudate-putamen 
(red arrows) of Thorase KO compared to wild type mice. B, Representative images of 
Oligo2/CC1 staining of the cortex of wildtype and Thorase KO mice (double positive 
cells indicated by white arrows). C, Representative images of optic nerves of wildtype 
and Thorase KO mice showing myelinated axons. D, Quantification of number of axons 
per image area of images in C (n = 12). E, Quantification of diameter of axons of images 
in c (n = 12). D, Quantification of number of myelin thickness of images in C (n = 12). 
mean ± standard error of the mean [SEM] of experiments performed, ***p < 0.001, n.s p 
> 0.05, ANOVA with Tukey-Kramer post-hoc test compared with wildtype. 
 
 74 
Chapter 4. Future directions 
The recent discovery of pathogenic variants that cause a recognizable neurological 
disease in newborns has given substantiation to the suspected importance of Thorase in 
protecting the brain. By uncovering an ever-increasing number of functions for Thorase, 
we are starting to understand that Thorase activity is required to ensure normal 
physiology in various cellular compartments. In particular, our study has revealed a new 
link between the survival and metabolism of neurons, which suggests that Thorase 
endows protection, at least partly, by maintaining neurons in a bioenergetically favorable 
state. While we have made commensurable progress in understanding the neuroprotective 
role of Thorase in the past few years, many intriguing questions remain to be answered 
that grant future research on Thorase. 
 
Expression and activity of Thorase in different tissues and cell types, 
and regulation thereof 
Zhang and colleagues first peeked into the relative expression of Thorase throughout the 
body (Zhang et al, 2011). They detected Thorase expression predominantly in the mouse 
brain and testis, with a high degree of expression variability in the brain. The striking 
neurological defects resulting from abnormal Thorase function in both mice and humans 
supports a prominent role of Thorase in the nervous system, with nuances. In mice, 
knocking out Thorase at the whole-body level leads to perinatal death, while animals with 
restricted Thorase deletion in the forebrain or midbrain are viable. This notion 
demonstrates the need for a more comprehensive analysis of Thorase actions in different 
brain cell types, including neuroglia. Generation of pertinent models using Thorase 
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lacking stem cells that can be differentiated into diverse cell types, or conditional 
knockout rodent models generated with inducible systems such as Cre-LoxP will enable 
to answer this fundamental question. 
 
Along the same lines, it will be interesting to investigate how divergent levels of Thorase 
expression across tissues can be achieved, whether this is transcriptionally or 
translationally regulated or due to additional factors that modulate Thorase degradation. 
A particularly intriguing idea is that Thorase expression or localization within the cell is 
regulated by the intracellular levels of ATP, that is, that Thorase could behave or act in 
tandem with an ATP-sensing molecule. This could potentially tie the regulation of mTOR 
signaling with the metabolic status of the cell.  
 
Furthermore, it will be insightful to understand whether any connection between different 
Thorase functions exist. For instance, mTORC1-dependent translation is required for 
synaptic plasticity, and mTORC1 has been suggested to regulate the surface expression 
of AMPAR (Wang et al, 2006). If in the absence of Thorase AMPAR endocytosis is 
impaired and excess mTORC1 activity leads to insertion of more AMPAR at the synapse, 
collectively this could explain the severe defects in neuronal excitability observed in mice 
and humans.   
 
Substrate selection and recognition by Thorase 
From studies with other AAA+ ATPases, it seems that cells can control one activity of a 
particular AAA+ protein without compromising other activities of the same AAA+ 
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protein through the usage of adaptor proteins. The many protein adaptors known for p97 
and the substrates they target p97 to exemplify this well (Stach & Freemont, 2017). It has 
been suggested that adaptor proteins tend to use a common platform, the N-terminal 
domain of AAA+ ATPases, for binding and regulating AAA+ activity.  
 
Although a recent study in the yeast homolog of Thorase, Msp1, indicated that Msp1 
alone could bind and extract mislocalized proteins from isolated liposomes (Wohlever et 
al, 2017), this in vitro study with isolated components hardly represents real cell 
physiology. Searching for adapters that shuttle Thorase to particular substrates in 
different subcellular localizations will be interesting and it will potentially explain 
whether Thorase exerts specialized functions in specific cell types, as regulation of 
adapter expression in a cell-dependent manner would allow for this. This same study 
suggested that Thorase recognizes exposed hydrophobic areas in their target proteins. 
Whether this is a generalizable substrate recognition mechanism for Thorase, or whether 
additional recognition motifs for it exist will help understand how Thorase operates and 
potentially bolster the discovery of additional substrates.  
 
Structural insight into Thorase activity 
Studies with the yeast homolog of Thorase, Msp1, have suggested that it oligomerizes 
into hexamers at the mitochondria (Wohlever et al, 2017). Whether Thorase also 
assembles into hexamers in mitochondria will be an important question to address. In 
addition, whether different Thorase functions are exerted by a common oligomeric 
conformation or whether functional specificity can stem from a diversification in Thorase 
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assembly is an idea worth testing. To answer this and other interesting questions, 
obtaining structural models of Thorase by nuclear magnetic resonance spectroscopy, X-
ray crystallography and cryo-electron microscopy will be pivotal. Performing these 
structural studies with Thorase alone or in coordination with its substrates, and in the 
presence of different nucleotides, will be an important step towards understanding how 
Thorase binds substrates, how it transduces the energy of ATP hydrolysis and how it 
localizes to different cell compartments. The use of ATP binding or hydrolyzing mutants 
Walker A and B, and variants of Thorase associated with human disease will provide 
additional information about the structural nature of Thorase interactions and activities. 
 
Investigation of the link between Thorase function and protein 
degradation 
A recurrent observation made by several studies is that, in the absence of Thorase, certain 
proteins it regulates abnormally accumulate, suggesting that in physiological conditions 
Thorase may couple the disassembly of complexes or extraction of proteins with their 
degradation. It will be important to determine what cellular degradation pathways this 
activity depends upon, whether it is the ubiquitin-proteasome system, the autophagy 
machinery or whether Thorase associates with particular proteases. A feasible alternative 
is that, given mTOR blockade of autophagy, the accumulation of Thorase substrates 
observed in its absence may be a by-product of its failure to negatively regulate mTORC1 
activity, which would involve a halt in autophagic flux. Genetically or pharmacologically 
ablating excess mTOR activity or inducing the activity of specific cellular degradation 
pathways could be a useful avenue to discern between all the above possibilities. 
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Phenotype-genotype relationship of emerging pathogenic Thorase 
variants 
Any disruption in gene or protein sequence that disrupts protein function can provide 
enormous insight into the normal activity of a protein. Through comparative studies 
between wild type Thorase and its human pathogenic variants, and combining 
biochemical and structural techniques, these mutants will add a new dimension to our 
understanding on the function of Thorase. To establish a genotype-phenotype relationship 
for these variants, the generation of mouse models or stem cells that contain these 
familial mutations using CRISPR gene editing technology will be key. Insights from 
studies discussed earlier on the specificity of Thorase in different tissues or cell-types 
will be a guiding reference to evaluate whether these variants should be induced 
ubiquitously or whether their expression should be spatial- and temporally restricted.
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